Last reviewed · How we verify
Placebo Eprosartan mesylate
Eprosartan mesylate is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure.
Eprosartan mesylate is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure. Used for Hypertension.
At a glance
| Generic name | Placebo Eprosartan mesylate |
|---|---|
| Also known as | Placebo |
| Sponsor | Abbott |
| Drug class | Angiotensin II receptor antagonist |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By blocking the angiotensin II receptor, eprosartan mesylate reduces the blood pressure by causing vasodilation and reducing the blood volume. This results in a decrease in the workload on the heart and a reduction in the risk of cardiovascular events.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
- Cough
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Eprosartan mesylate CI brief — competitive landscape report
- Placebo Eprosartan mesylate updates RSS · CI watch RSS
- Abbott portfolio CI